Ann: Kazia Annual Report to shareholders, page-18

Agreed, considering the number of employees in Kazia's team, and to prioritize their time to assist Simcere in their NMPA paxalisib submission, would have been a condition of the licensing agreement so that a number of GBM AGILE trials can commence in China latter this year.

"As the drug proceeds through development, further milestone payments will be reinvested by Kazia in the global paxalisib program"
What is Kazia's global paxalisib program?

Regards.